BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Moves to Acquire ‘Safety Shot’ – the World’s First Rapid Blood Alcohol Detox Drink

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced it has executed an asset purchase agreement with GBB Drink Lab Inc. Under the agreement, all operating assets related to GBB Drink Lab, including the revolutionary Safety Shot beverage, will belong to Jupiter Wellness. Safety Shot, which is protected by a number of issued and pending patents covering composition of matter and methods of use, creates a new product category for rapid alcohol detoxification in the fast-growing hangover remedy market. “The world-first breakthrough nature of Safety Shot and the market it addresses are a tremendous opportunity that Jupiter will effectively execute upon,” said Jupiter Wellness CEO Brian John. “This asset purchase is a truly transformational transaction for the company and its shareholders.”

To view the full press release, visit https://ibn.fm/gTvs4

About Jupiter Wellness Inc.

Jupiter Wellness, a wellness company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sells its products through third-party physical retail stores and partners. The company was formerly known as CBD Brands Inc. Jupiter Wellness Inc. was incorporated in 2018 and is headquartered in Jupiter, Florida. For more information, visit the company’s website at www.JupiterWellness.com.

NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Rare Biotech Story: Nutriband Inc. (NASDAQ: NTRB) Featured on Smart Money Podcast

Nutriband (NASDAQ: NTRB) was recently featured on the Smart Money Circle Show, where Serguei Melnik, NTRB’s founder…

2 days ago

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in NetworkNewsWire Spotlight on Genetic Medicines 

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech innovator, announced its inclusion in an editorial…

2 days ago

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Raises $4.6 Million Through Warrant Exercise Agreement

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech firm developing targeted therapies for genetic medicine…

3 days ago

BioMedNewsBreaks — Adageis’ Platform Tackles Healthcare Complexities with AI

Adageis was featured in a recent article that discussed its powerful and patented AI-centric software solution.…

4 days ago

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Lead Program in Virtual CEO Segment 

  CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on treating primary and metastatic cancers…

4 days ago

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets Multiple 2025–2026 Catalysts Across Rare Disease Pipeline

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical…

4 days ago